Please assess the completion status of the following clinical trial:

Trial Title: Treating Acute Pancreatitis With Dabigatran, a Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Acute Pancreatitis (presence at least two of three features: typical pain, amylase or lipase \>3 times UNL and AP on images)~* 18-75 years old~* Willingness to sign the informed consent~* Symptom onset within 72 hours~Exclusion Criteria:~* Under 18 years of age or over 75 years of age~* Pregnancy or lactating~* Presence of pseudo aneurysm on CT~* Predicted severe acute pancreatitis~* Unwilling or unable to sign the informed consent~* Had recent surgery or sphincterotomy~* Active pathological bleeding~* Concurrent use of anti-coagulation~* Known serious hypersensitivity reaction to Dabigatran~* CrCI \<30mL/min or on dialysis~* Mechanical prosthetic valves~* Liver disease~* Cancer~* On Chemotherapy or immunosuppressant~* Persistent ALT, AST, Akl Phos \>2 x ULN~* Active hepatitis C, active hepatitis B, and active hepatitis A~* Anemia (hemoglobin \<10g/dL)~* Thrombocytopenia~* Concomitant use of P-gp inhibitors

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Dabigatran Etexilate Mesylate (Type: ACTIVE_COMPARATOR): Dabigatran 150mg BID for 3 days
- Standard of Care (Type: ACTIVE_COMPARATOR): Standard treatment for acute pancreatitis

Based on this trial design, predict the completion outcome and termination type (if applicable).